Yihua Gu

发表

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

B. Strober, A. Kimball, A. Menter, 2008, Journal of the American Academy of Dermatology.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

E. H. Thompson, B. Strober, M. Lebwohl, 2018, The Lancet.

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

E. H. Thompson, M. Gooderham, K. Reich, 2019, The Lancet.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo‐controlled trial

B. Elewski, K. Papp, Y. Poulin, 2018, Journal of the American Academy of Dermatology.

Predictive Biomarker Identification for Biopharmaceutical Development

Yihua Gu, Xin Huang, Hesen Li, 2020 .

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

J. Silverberg, K. Papp, K. Reich, 2019, Journal of Allergy and Clinical Immunology.

Adalimumab treatment optimization for psoriasis: Results of a long‐term phase 2/3 Japanese study

H. Nakagawa, M. Ohtsuki, M. Okun, 2015, The Journal of dermatology.

A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study.

S. Block, Yihua Gu, M. Cifaldi, 2005, Clinical therapeutics.

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.

E. Sasso, K. Papp, K. Gordon, 2012, Journal of the American Academy of Dermatology.

Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints

E. Slate, Jian Kang, Yiwang Zhou, 2020, Journal of biopharmaceutical statistics.

Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.

B. Strober, K. Papp, F. Kerdel, 2011, Journal of the American Academy of Dermatology.

Long‐term adalimumab efficacy in patients with moderate‐to‐severe hidradenitis suppurativa/acne inversa: 3‐year results of a phase 3 open‐label extension study

C. Zouboulis, G. Jemec, P. Foley, 2019, Journal of the American Academy of Dermatology.

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.

A. Menter, K. Gordon, C. Leonardi, 2010, Journal of the American Academy of Dermatology.

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab

A. Armstrong, Yihua Gu, O. Reyes Servín, 2016, American Journal of Clinical Dermatology.

Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial

M. Lebwohl, K. Gordon, M. Okun, 2011 .

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

A. Paller, K. Papp, E. Simpson, 2021, The Lancet.

A practical response adaptive block randomization (RABR) design with analytic type I error protection

Lanju Zhang, Yihua Gu, Lu Cui, 2020, Statistics in medicine.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

A. Gottlieb, A. Kimball, A. Armstrong, 2016, The New England journal of medicine.

Uncovering burden disparity: A comparative analysis of the impact of moderate‐to‐severe psoriasis and hidradenitis suppurativa

S. Arikian, M. Sundaram, A. Ganguli, 2017, Journal of the American Academy of Dermatology.

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

B. Strober, K. Papp, K. Reich, 2011, American journal of clinical dermatology.

Exploratory Subgroup Identification for Biopharmaceutical Development

Yan Sun, Xin Huang, Ivan S. F. Chan, 2020 .

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

A. Kimball, J. Schlessinger, C. Zouboulis, 2012, Annals of Internal Medicine.

Y. Poulin, Yihua Gu, H. Teixeira, 2014, Dermatology and Therapy.

Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.

A. Menter, A. Navarini, Y. Poulin, 2014, Journal of drugs in dermatology : JDD.

Original Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial

Martin, M. Sundaram, Yihua Gu, 2016 .

Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.

M. Sundaram, M. Okun, Yihua Gu, 2016, Dermatology online journal.

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.

B. Strober, A. Gottlieb, K. Papp, 2012, The Journal of investigative dermatology.

Younger Than 55 Years Old and BRAF V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm

Jiaqin Deng, Yihua Gu, Ming-Tsong Yu, 2023, International journal of general medicine.

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

A. Paller, J. Thyssen, K. Yamamoto‐Hanada, 2023, JAMA dermatology.

Treatment of Moderate to Severe Hidradenitis Suppurativa

A. Kimball, M. Okun, Yihua Gu, 2013, Annals of Internal Medicine.

Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study

K. Papp, M. Sundaram, Yihua Gu, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

J. Ortonne, K. Papp, R. Langley, 2011, The British journal of dermatology.

Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities

A. Kimball, C. Zouboulis, F. Kerdel, 2014, The British journal of dermatology.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

A. Kimball, G. Jemec, M. Sundaram, 2014, The British journal of dermatology.

Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.

A. Gottlieb, A. Armstrong, A. Menter, 2016, Journal of drugs in dermatology : JDD.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

A. Gottlieb, A. Kimball, A. Armstrong, 2016, The New England journal of medicine.

An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiency

Lanju Zhang, Yihua Gu, Lu Cui, 2021, Statistical methods in medical research.

A Practical Response Adaptive Block Randomization Design with Analytic Type I Error Protection

Lu Cui, Tianyu Zhan, Ziqian Geng, 2020 .